PMID- 34547555
OWN - NLM
STAT- MEDLINE
DCOM- 20220204
LR  - 20220204
IS  - 1879-0593 (Electronic)
IS  - 1368-8375 (Linking)
VI  - 122
DP  - 2021 Nov
TI  - Do all patients with locoregionally advanced nasopharyngeal carcinoma benefit 
      from the maintenance chemotherapy using S-1/capecitabine?
PG  - 105539
LID - S1368-8375(21)00645-X [pii]
LID - 10.1016/j.oraloncology.2021.105539 [doi]
AB  - BACKGROUND: The goal of this study was to explore the benefits of 
      S-1/capecitabine as maintenance therapy in locoregionally advanced nasopharyngeal 
      carcinoma (NPC) patients with different risks of treatment failure. METHODS: A 
      total of 2205 eligible, locoregionally advanced NPC patients were recruited for 
      this retrospective study. Multivariate Cox regression analysis was performed to 
      identify optimal predictors of overall survival (OS) and distant metastasis-free 
      survival (DMFS) for constructing the nomograms. Patients were stratified into 
      high-risk or low-risk groups based on the total score of the nomograms. 
      Propensity score matching (PSM) was performed to match the maintenance and 
      non-maintenance cohorts in different risk groups. A log-rank test was performed 
      to evaluate correlations between maintenance therapy and survival. RESULTS: A 
      nomogram for OS was established (C-index, 0.664; 95% confidence interval, 
      0.635-0.693). The 5-year OS rate was significantly higher in the low-risk group 
      than in the high-risk group (83.5% vs. 67.2%, P < 0.001). Patients in the 
      high-risk group who received S-1/capecitabine maintenance therapy achieved 
      significant improvement in the 5-year OS rate (82.8% vs. 67.1%, p = 0.034), 
      whereas patients in the low-risk group did not (86.7% vs. 80.9%, P = 0.081). 
      There was no significant difference in OS, DMFS, progression-free survival (PFS), 
      or toxicities between the S-1 and capecitabine groups (all P > 0.05), and overall 
      treatment-related adverse events (AEs) were not severe (grade 1-2). CONCLUSION: 
      S-1/capecitabine maintenance therapy could prolong OS for locoregionally advanced 
      NPC patients in the high-risk group. The toxicities of S-1/capecitabine 
      maintenance therapy were mild and tolerable. Our findings can help guide 
      maintenance therapy in locoregionally advanced NPC.
CI  - Copyright (c) 2021 Elsevier Ltd. All rights reserved.
FAU - Zhu, Man-Yi
AU  - Zhu MY
AD  - Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South 
      China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key 
      Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Road 
      East, Guangzhou 510060, PR China; Department of Nasopharyngeal Carcinoma, Sun 
      Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, PR 
      China. Electronic address: zhumany@sysucc.org.cn.
FAU - Sun, Xue-Song
AU  - Sun XS
AD  - Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South 
      China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key 
      Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Road 
      East, Guangzhou 510060, PR China; Department of Nasopharyngeal Carcinoma, Sun 
      Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, PR 
      China. Electronic address: sunxs@sysucc.org.cn.
FAU - Guo, Shan-Shan
AU  - Guo SS
AD  - Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South 
      China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key 
      Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Road 
      East, Guangzhou 510060, PR China; Department of Nasopharyngeal Carcinoma, Sun 
      Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, PR 
      China. Electronic address: guoshsh@sysucc.org.cn.
FAU - Chen, Qiu-Yan
AU  - Chen QY
AD  - Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South 
      China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key 
      Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Road 
      East, Guangzhou 510060, PR China; Department of Nasopharyngeal Carcinoma, Sun 
      Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, PR 
      China. Electronic address: chenqy@sysucc.org.cn.
FAU - Tang, Lin-Quan
AU  - Tang LQ
AD  - Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South 
      China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key 
      Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Road 
      East, Guangzhou 510060, PR China; Department of Nasopharyngeal Carcinoma, Sun 
      Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, PR 
      China. Electronic address: tanglq@sysucc.org.cn.
FAU - Liu, Li-Ting
AU  - Liu LT
AD  - Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South 
      China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key 
      Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Road 
      East, Guangzhou 510060, PR China; Department of Nasopharyngeal Carcinoma, Sun 
      Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, PR 
      China. Electronic address: liult@sysucc.org.cn.
FAU - Mai, Hai-Qiang
AU  - Mai HQ
AD  - Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South 
      China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key 
      Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Road 
      East, Guangzhou 510060, PR China; Department of Nasopharyngeal Carcinoma, Sun 
      Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, PR 
      China. Electronic address: maihq@mail.sysu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210920
PL  - England
TA  - Oral Oncol
JT  - Oral oncology
JID - 9709118
RN  - 6804DJ8Z9U (Capecitabine)
SB  - IM
MH  - *Capecitabine/therapeutic use
MH  - Chemoradiotherapy
MH  - Humans
MH  - *Maintenance Chemotherapy
MH  - *Nasopharyngeal Carcinoma/drug therapy
MH  - *Nasopharyngeal Neoplasms/drug therapy
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Capecitabine
OT  - Epstein-Barr virus
OT  - Locoregionally advanced nasopharyngeal carcinoma
OT  - Maintenance therapy
OT  - Nomogram
OT  - Propensity score matching
OT  - S-1
EDAT- 2021/09/22 06:00
MHDA- 2022/02/05 06:00
CRDT- 2021/09/21 20:19
PHST- 2021/07/14 00:00 [received]
PHST- 2021/08/30 00:00 [revised]
PHST- 2021/09/10 00:00 [accepted]
PHST- 2021/09/22 06:00 [pubmed]
PHST- 2022/02/05 06:00 [medline]
PHST- 2021/09/21 20:19 [entrez]
AID - S1368-8375(21)00645-X [pii]
AID - 10.1016/j.oraloncology.2021.105539 [doi]
PST - ppublish
SO  - Oral Oncol. 2021 Nov;122:105539. doi: 10.1016/j.oraloncology.2021.105539. Epub 
      2021 Sep 20.